Moreover, combining two or more individual biomarkers as a panel could obtain a better predictive value for NASH, and in a design including CK-18 and FGF-21, the AUROC was 0.95 compared to the CK-18 or FGF-21 assay, with the combined (from seven studies) sensitivity and specificity being 0.92 and 0.85, respectively [41]. This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatohepatitis.